Metelimumab

Drug Profile

Metelimumab

Alternative Names: Anti-TGF-β - Genzyme; Anti-TGF-β-1 monoclonal antibody - Cambridge Antibody Technology; Anti-transforming-growth-factor-beta-1 monoclonal antibody - Cambridge Antibody Technology; CAT-192; Human anti-TGF-β-1 monoclonal antibody - Cambridge Antibody Technology; SL-15; Sl15; TGF-β-1 monoclonal antibody - Cambridge Antibody Technology

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Scleroderma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Fibrosis; Scleroderma

Most Recent Events

  • 16 May 2005 Discontinued - Phase-I for Fibrosis in United Kingdom (Injection)
  • 16 May 2005 Discontinued - Phase-I/II for Scleroderma in USA (Infusion)
  • 16 May 2005 Discontinued - Phase-II for Scleroderma in Europe (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top